Adjuvant systemic therapy: state of the art, 1989.

Abstract:

:After more than 100 reported randomized trials of systemic adjuvant therapy in breast cancer, it is clear that this therapy will prolong the time to recurrence and the survival time significantly, at least in some patient subsets. But there is less than complete agreement as to which subsets, which therapies, how much benefit can be achieved, and when (if ever) the risk/benefit ratio may not favor this approach. The results of these trials, and some trials still in progress, are summarized, and the current understanding of the role of systemic adjuvant therapy for breast cancer is reviewed.

authors

Henderson IC

doi

10.1007/BF01805971

subject

Has Abstract

pub_date

1989-10-01 00:00:00

pages

3-22

issue

1

eissn

0167-6806

issn

1573-7217

journal_volume

14

pub_type

临床试验,杂志文章,随机对照试验,评审
  • Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer.

    abstract:PURPOSE:The epithelial-mesenchymal transition (EMT) plays a key role in breast cancer progression and metastasis. Lipocalin 2 (LCN2) is involved in the regulation of EMT. The aim of this study was to investigate the clinicopathological significance of LCN2 expression in breast cancer. METHODS:The expression of LCN2 pr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05488-2

    authors: Kurozumi S,Alsaeed S,Orah N,Miligy IM,Joseph C,Aljohani A,Toss MS,Fujii T,Shirabe K,Green AR,Aleskandarany MA,Rakha EA

    更新日期:2020-02-01 00:00:00

  • Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.

    abstract::The pharmacokinetics of free and different liposomal formulations of hexadecylphosphocholine (HPC) was investigated in tumor-bearing (human mammary tumor MaTu) and tumor-free mice after intravenous and intraperitoneal administration. The levels of HPC were evaluated at different times in serum, normal tissues, and tum...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006224611505

    authors: Arndt D,Zeisig R,Fichtner I,Teppke AD,Fahr A

    更新日期:1999-11-01 00:00:00

  • Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18-64 years in BCBS of Texas.

    abstract:PURPOSE:The objective of this study is to understand an impact of financial burden on the adjuvant hormonal therapy (AHT) adherence and persistence for insured women aged 18-64 with early breast cancer in Texas. METHODS:We conducted a retrospective cohort study using claims data for population insured by Blue Cross Bl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4704-3

    authors: Kim J,Rajan SS,Du XL,Franzini L,Giordano SH,Morgan RO

    更新日期:2018-06-01 00:00:00

  • Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.

    abstract:BACKGROUND:The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications. PATIENTS AND METHODS:In all, 541 pati...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05746-8

    authors: Walter V,Fischer C,Deutsch TM,Ersing C,Nees J,Schütz F,Fremd C,Grischke EM,Sinn P,Brucker SY,Schneeweiss A,Hartkopf AD,Wallwiener M

    更新日期:2020-08-01 00:00:00

  • A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.

    abstract::The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer. This phase 3, randomized, double-blind study directly compared time to progression (TTP) for exemestane and anastrozole therapy in this p...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-013-2573-3

    authors: Iwata H,Masuda N,Ohno S,Rai Y,Sato Y,Ohsumi S,Hashigaki S,Nishizawa Y,Hiraoka M,Morimoto T,Sasano H,Saeki T,Noguchi S

    更新日期:2013-06-01 00:00:00

  • Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.

    abstract:PURPOSE:In our microarray analysis we observed that Seven-in-Absentia Homolog 2 (SIAH2) levels were low in estrogen receptor (ER) positive breast tumors of patients resistant to first-line tamoxifen therapy. The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0125-z

    authors: Jansen MP,Ruigrok-Ritstier K,Dorssers LC,van Staveren IL,Look MP,Meijer-van Gelder ME,Sieuwerts AM,Helleman J,Sleijfer S,Klijn JG,Foekens JA,Berns EM

    更新日期:2009-07-01 00:00:00

  • Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV-VI.

    abstract:PURPOSE:This study aimed to examine the prevalence and trends of breast cancer-related risk factors and characteristics in premenopausal underweight Korean women according to birth year cohort. METHODS:Socioeconomic and breast cancer-related risk factors were investigated in 13,415 premenopausal women using nationwide...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-05091-x

    authors: Kim JH,Yoon KH,Hur H,Park S,Kim JY,Park HS,Kim SI,Cho YU,Park BW

    更新日期:2019-04-01 00:00:00

  • Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.

    abstract::Abnormal translation of mRNAs frequently occurring during carcinogenesis is among the mechanisms that can affect the expression of proteins involved in tumor development and progression. Eukaryotic initiation factor eIF4E is a key regulator of translation of many cancer-related transcripts and its expression is altere...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2671-2

    authors: Heikkinen T,Korpela T,Fagerholm R,Khan S,Aittomäki K,Heikkilä P,Blomqvist C,Carpén O,Nevanlinna H

    更新日期:2013-08-01 00:00:00

  • Reversed urban-rural differences in breast cancer mortality (China, 2002-2008).

    abstract::The purpose of this study was to examine the urban-rural difference in breast cancer mortality between 2002 and 2008 in China. A longitudinal analysis of mortality data was performed. Mortality data were extracted from Chinese Health Statistics Yearbook. Linear regression was used to examine the statistical significan...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1276-2

    authors: He M,Guo Q,Hu G

    更新日期:2011-02-01 00:00:00

  • Salvage chemotherapy in metastatic breast cancer: an experience with the combination of mitoxantrone, 5-fluorouracil, and L-leucovorin.

    abstract::From January 1992 to July 1993, 28 patients with metastatic breast cancer were entered in a phase II trial to assess the activity and toxicity of the combination of mitoxantrone, 5-fluoruracil, and leucovorin. Patients were eligible if they had progressive disease after either adjuvant (2 patients) or previous chemoth...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF01806146

    authors: Colozza M,Gori S,Mosconi AM,Anastasi P,Basurto C,Ludovini V,De Angelis V,Giansanti M,Tonato M

    更新日期:1996-01-01 00:00:00

  • A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (

    abstract:PURPOSE:Suberoylanilide hydroxamic acid (SAHA; vorinostat), a small molecule inhibitor of histone deacetylase, attenuates signaling pathways known to confer trastuzumab resistance. A combination of SAHA and trastuzumab may be a promising strategy to improve the efficacy of trastuzumab against breast cancer. In this Pha...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4310-9

    authors: Goldstein LJ,Zhao F,Wang M,Swaby RF,Sparano JA,Meropol NJ,Bhalla KN,Pellegrino CM,Katherine Alpaugh R,Falkson CI,Klein P,Sledge GW

    更新日期:2017-09-01 00:00:00

  • Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread.

    abstract::The early spread of tumor cells in primary breast cancer patients may occur either through lymphatic or hematogenous dissemination. Lymph node (LN) status and presence of disseminated tumor cells (DTC) in bone marrow (BM) are independent predictors of poor outcome. It is unknown which factors determine one or the othe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1802-x

    authors: Hartkopf AD,Banys M,Krawczyk N,Staebler A,Becker S,Hoffmann J,Hahn M,Wallwiener M,Fehm T

    更新日期:2012-01-01 00:00:00

  • Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657).

    abstract:PURPOSE:The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis may contribute to the development of bone metastases (BM). We studied gene expression in this pathway in primary breast cancer (BC) to determine correlations with clinical characteristics and outcomes in the n...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-017-4318-1

    authors: Vidula N,Yau C,Li J,Esserman LJ,Rugo HS

    更新日期:2017-08-01 00:00:00

  • Antibodies to 46-kDa retinal antigen in a patient with breast carcinoma and cancer-associated retinopathy.

    abstract::Cancer-associated retinopathy (CAR) is a rare paraneoplastic syndrome usually associated with small-cell lung carcinoma and serum autoantibodies against recovering. We report the breast cancer woman with visual impairments and electrophysiological abnormalities characteristic of CAR. Her serum contained high-titer ant...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9721-6

    authors: Ejma M,Misiuk-Hojło M,Gorczyca WA,Podemski R,Szymaniec S,Kuropatwa M,Rogozińska-Szczepka J,Bartnik W

    更新日期:2008-07-01 00:00:00

  • Validity of self-reports of breast cancer treatment in low-income, medically underserved women with breast cancer.

    abstract::Few studies have assessed the agreement between subjects' self-report and medical records among patients with breast cancer (BC), and none has addressed this issue in low-income women with BC. We assessed the level of agreement between self-report and medical records data for key BC treatment and prognostic characteri...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0447-5

    authors: Liu Y,Diamant AL,Thind A,Maly RC

    更新日期:2010-02-01 00:00:00

  • A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7.

    abstract::Bone morphogenetic proteins (BMPs) regulate diverse cellular processes, such as proliferation, differentiation, and apoptosis. The BMPs have been studied in several cancers, but thus far contradictory results have been obtained and, especially in breast cancer, information on BMPs is still limited. We performed a syst...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9362-1

    authors: Alarmo EL,Kuukasjärvi T,Karhu R,Kallioniemi A

    更新日期:2007-06-01 00:00:00

  • The androgen metabolite 5alpha-androstane-3beta,17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance.

    abstract::The aromatase inhibitors (AIs) are used to treat estrogen receptor-positive (ER+) breast tumors in post-menopausal women, and function by blocking the conversion of adrenal androgens to estrogens by the enzyme CYP19 aromatase. Breast cancer patients receiving AI therapy have circulating estrogen levels below the level...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-0080-8

    authors: Sikora MJ,Cordero KE,Larios JM,Johnson MD,Lippman ME,Rae JM

    更新日期:2009-05-01 00:00:00

  • Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy.

    abstract::We report a series of breast cancer patients with invasive skin and nail infections with Staphylococcus species that we attribute to the addition of pertuzumab to trastuzumab-based therapy. With the suspicion of an increased incidence of cutaneous infection in patients treated with pertuzumab and trastuzumab-based che...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-014-3190-5

    authors: Mortimer J,Jung J,Yuan Y,Kruper L,Stewart D,Chung S,Yu KW,Mendelsohn M,D'Apuzzo M,Tegtmeier B,Dadwal S

    更新日期:2014-12-01 00:00:00

  • Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer.

    abstract::Circulating tumor cells are commonly observed in the peripheral blood of advanced breast cancer patients. We tested the feasibility of tumor cell detection in the cerebrospinal fluid (CSF) and studied its clinical relevance in leptomeningeal metastasis (LM) of breast cancer. CSF samples were collected from 38 metastat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3610-1

    authors: Lee JS,Melisko ME,Magbanua MJ,Kablanian AT,Scott JH,Rugo HS,Park JW

    更新日期:2015-11-01 00:00:00

  • Down-regulation of the CD3-zeta chain in sentinel node biopsies from breast cancer patients.

    abstract:BACKGROUND:In several neoplastic diseases, immunosuppression has been shown to correlate with disease stage, progression, and outcome. As the prognosis for metastatic breast cancer is still pessimistic, additional strategies are being sought to improve survival. Local immunosuppression in sentinel node biopsies from 24...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1016009913699

    authors: Schüle J,Bergkvist L,Håkansson L,Gustafsson B,Håkansson A

    更新日期:2002-07-01 00:00:00

  • Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.

    abstract:PURPOSE:Triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy (NAC) harbor higher risk of relapse, and eventual demise compared to those who achieve pathologic complete response. Therefore, in this study, we assessed a panel of molecules involved in key pathways of drug ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4985-6

    authors: Guestini F,Ono K,Miyashita M,Ishida T,Ohuchi N,Nakagawa S,Hirakawa H,Tamaki K,Ohi Y,Rai Y,Sagara Y,Sasano H,McNamara KM

    更新日期:2019-01-01 00:00:00

  • Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients.

    abstract::The plasma urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator receptor (uPAR) levels were measured in healthy volunteers and breast cancer patients. In pre-menopause healthy females, blood was sampled weekly during one menstruation cycle and ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005997421733

    authors: Chung HC,Rha SY,Park JO,Yoo NC,Kim JH,Roh JK,Min JS,Lee KS,Kim BS,Kim JJ

    更新日期:1998-05-01 00:00:00

  • Outcomes of a weight loss intervention among rural breast cancer survivors.

    abstract::Obese breast cancer survivors have increased risk of recurrence and death compared to their normal weight counterparts. Rural women have significantly higher obesity rates, thus weight control intervention may be a key strategy for prevention of breast cancer recurrence in this population. This one-arm treatment study...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s10549-011-1922-3

    authors: Befort CA,Klemp JR,Austin HL,Perri MG,Schmitz KH,Sullivan DK,Fabian CJ

    更新日期:2012-04-01 00:00:00

  • Diet and risk for breast cancer recurrence and survival.

    abstract::Dietary factors may influence the risk for breast cancer and also the prognosis following diagnosis and treatment. The aim of this study was to assess whether self-reported prediagnosis diet or other patient factors associated with breast cancer incidence were predictive of recurrence and survival. Patients (n = 149) ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1006190820231

    authors: Saxe GA,Rock CL,Wicha MS,Schottenfeld D

    更新日期:1999-02-01 00:00:00

  • Targeting the EGF receptor in breast cancer treatment.

    abstract::Immunotoxins are a relatively new class of cytotoxic agents consisting of a catalytic toxin linked to an appropriate targeting ligand. The ligand directs the toxin to the surface of a tumor cell, whereupon the toxin enters the cell and catalytically inactivates the ribosome, thus disrupting protein synthesis and effec...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/BF00666210

    authors: LeMaistre CF,Meneghetti C,Howes L,Osborne CK

    更新日期:1994-01-01 00:00:00

  • Pre-operative progesterone benefits operable breast cancer patients by modulating surgical stress.

    abstract:PURPOSE:We have reported a survival benefit of single injection of hydroxyprogesterone prior to surgery for primary tumour in patients with node-positive operable breast cancer. Hydroxyprogesterone was meant to recapitulate the luteal phase of menstrual cycle in these women. We wanted to understand the molecular basis ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4749-3

    authors: Chatterjee S,Chaubal R,Maitra A,Gardi N,Dutt A,Gupta S,Badwe RA,Majumder PP,Pandey P

    更新日期:2018-07-01 00:00:00

  • Carotenoids and breast cancer risk: a meta-analysis and meta-regression.

    abstract::The purpose of this article is to comprehensively summarize the associations between carotenoids and breast cancer and quantitatively estimate their dose-response relationships. We searched PubMed, Embase, and Cochrane databases (from January 1982 to 1 May 2011) and the references of the relevant articles in English w...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-011-1723-8

    authors: Hu F,Wang Yi B,Zhang W,Liang J,Lin C,Li D,Wang F,Pang D,Zhao Y

    更新日期:2012-01-01 00:00:00

  • Lack of association between catechol-O-methyltransferase Val108/158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls.

    abstract::Epidemiological studies have evaluated the association between catechol-O-methyltransferase (COMT) Val108/158Met polymorphism and breast cancer risk. However, the results remain conflicting rather than conclusive. In order to derive a more precise estimation of the relationship, we performed this meta-analysis. System...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-009-0650-4

    authors: Mao C,Wang XW,Qiu LX,Liao RY,Ding H,Chen Q

    更新日期:2010-06-01 00:00:00

  • HER-2/neu expression in primary and metastatic breast cancer.

    abstract::Introduction Trastuzumab is a highly effective therapy for the treatment of HER-2/neu positive breast cancer. To maximize benefit and minimize unnecessary toxicity, patient selection is essential. Currently HER-2/neu analysis is routinely performed only for primary invasive breast cancers, and trastuzumab therapy is r...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-008-9931-6

    authors: Lower EE,Glass E,Blau R,Harman S

    更新日期:2009-01-01 00:00:00

  • Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery.

    abstract:PURPOSE:A positive margin after breast conserving surgery has consistently been shown to be a significant predictor for ipsilateral breast tumor recurrence. Currently, there is no standard for intraoperative margin assessment during lumpectomy, and up to 20% of cases result in positive margins. MarginProbe is a device ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05773-5

    authors: LeeVan E,Ho BT,Seto S,Shen J

    更新日期:2020-08-01 00:00:00